Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | GOT1 | P17174 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30461578 | 0.84 | HDAC1 (0.35) | GOT1HDAC1HDAC6HDAC5P2RX7 | |
| SCHEMBL30226513 | 0.80 | ALDH1A1 (0.42) | GOT1HDAC1HDAC6HDAC5P2RX7 | |
| SCHEMBL30225243 | 0.80 | ALDH1A1 (0.42) | GOT1HDAC1HDAC6HDAC5P2RX7 | |
| SCHEMBL4276013 | 0.80 | NPC1 (0.39) | KDM4EMAPK1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL23975682 | 0.78 | TSHR (0.39) | HDAC1HDAC6HDAC5P2RX7CLK4 | |
| SCHEMBL4272287 | 0.78 | CYP2D6 (0.44) | KDM4ELTA4HRAB9ACYP1A2 | |
| SCHEMBL18202622 | 0.78 | KDM4E (0.52) | TAAR1KDM4ELTA4HPLA2G2AHTR1B | |
| SCHEMBL898231 | 0.77 | SOAT1 (0.44) | LTA4HRAB9ASMN1; SMN2 | |
| SCHEMBL34469739 | 0.77 | HDAC1 (0.34) | GOT1HDAC1HDAC6HDAC5P2RX7 | |
| SCHEMBL29415429 | 0.77 | ALDH1A1 (0.34) | KDM4EHDAC1HDAC6HDAC5P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563073-B | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| EP-3475268-B1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3475268-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017220799-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2017-12-28 | — | — | WO | disclosed |
| EP-3260452-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2017-12-27 | — | — | EP | disclosed |
| EP-1885695-B8 | INDOLINE COMPOUNDS | FOURNIER LAB SA (FR) | 2009-08-12 | — | — | EP | disclosed |
| EP-1885695-B1 | INDOLINE COMPOUNDS | FOURNIER LAB SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-1885695-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007000550-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-01-04 | — | — | WO | disclosed |
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| EP-1317459-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020530-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | TAAR1 2703/4885KDM4E 433/4885LTA4H 4494/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TAAR1 509/4885KDM4E 1574/4885LTA4H 1742/4885 |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | HTR5A, HTR1A, HTR1E | TAAR1 110/4885KDM4E 2557/4885LTA4H 1141/4885 |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR1E | TAAR1 110/4885KDM4E 2557/4885LTA4H 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.